The clinical study
The Beta3_LVH project is a multi-centric, prospective, randomised, placebo-controlled phase IIb clinical trial testing the additional beneficial effect of a new agonist at β3-adrenergic receptors, versus placebo on top of a standard treatment.
The targeted population is constituted of patients carrying structural cardiac disease with or without symptoms of heart failure (up to NYHA II), i.e. at risk of developing heart failure with preserved ejection fraction (HFpEF).
In addition, the effect of the drug will be measured both on endothelial function and on the abundance/activity of beige/brown fat; because of the increasingly recognised paracrine influence of the endothelium on cardiac remodelling and the recent (re)discovery of human beige/brown fat that may influence peripheral and cardiac metabolism.